| System strengthening through support for surveillance and laboratory infrastructure in the Republic of Zambia under the President’s Emergency Plan for AIDS Relief (PEPFAR) CDC-RAFA-GH16-1671 for TDRC (HLAB and Surveillance of HIV)., P.I.- Dr. Gershom Chongwe, Mathias Tembo, Innocent C. Bwalya, Ngula M. Kabelenga, Kabengele Siame | To strengthen Systems through support for surveillance and laboratory infrastructure for HIV and TB/ Opportunistic Infection. | CDC | $200,000 | For the period September 01, 2020 through September 30, 2021 | SI-HIV component was funded but HLAB approved and funding expected from Carryover application for $300,000.00 Carryover was written and submitted to CDC awaiting Notice of Award. |
| World Bank/MOH operational research on TB in Mines Outcome of Miners and Ex-miners on the Copperbelt province Zambia. PIs-Mathias Tembo & Clara C. Kasapo Co-investigator: Dr. G Chongwe, Dr. Patrick Lungu | To determine the TB outcome of Miners and Ex –miners on the Copperbelt | World Bank, MOH | $30,000 | 2018 to 2021 | Reviewing of Data for Final Report and Manuscript drafting in progress |
| ZAcTHIM- Zambia ACTION for TB and HIV in the Mines Dr. Brittany Moore, Dr. Gershom Chongwe, Mathias Tembo, Kelvin Kapungu, Shepherd Khondowe, David Mwakazanga, Sydney Mwanza | To conduct sensitization of the communities of Miners and Ex-miners on TB in the mines | CDC (special project funding) | $135,000 | 2021 | Project concept revised from survey to community TB/HIV program implementation to raise awareness. (Awaiting NOA to resume activities) |
| Effects of metronidazole plus intermittent preventive treatment of malaria in pregnancy on birth outcomes: a randomised controlled trial in Zambia (ASPIRE Study), PI-Dr. Mike Chaponda, CO-Investigators: Dr S. Hachizovu, Dr Michael Nambozi, Dr Enesia Chaponda-Ngulube, Prof Modest Mulenga | To determine whether the combination of metronidazole (MTZ) with intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine (IPTp-SP) or dihydroartemisinin-piperaquine (IPTp-DP) is superior to IPTp-SP alone in reducing adverse pregnancy outcomes related to malaria, bacterial vaginosis (BV), and Trichomonas vaginalis (TV) infections in pregnancy. | Funder: Medical Research Council, UK, Sponsor: London School of Hygiene & Tropical Medicine | £1,558,000 | 17th Dec 2019 to 30th June 2023 | |
| Measles and Rubella Vaccination Campaign Sero-survey in Select Districts in Zambia, PI: William Moss, Co Investigators: Kyla Hayford, Simon Mutembo, Andrea Carcelen, Shaun Truelove, Gershom Chongwe, Francis Mwansa, Phillimon Ndubani, Philip Thuma | To measure the proportion of children vaccinated at selected health care facilities during the measles and rubella SIA who are susceptible to measles and rubella, and the feasibility and acceptability of collecting dried blood spots (DBS) from children at the point of vaccination during an SIA. | Bill and Melinda Gates Foundation through Johns Hopkins University | $87,000 | Sept 2020 – March 2021 | |
| Flexible Serological Surveillance System in Zambia William Moss, Co Investigators: Simon Mutembo, Andrea Carcelen, Shaun Truelove, Gershom Chongwe, Francis Mwansa, Phillimon Ndubani, Philip Thuma | To assess the feasibility of using a Flexible Serological Surveillance System for Measles, Rubella and other pathogens in Zambia | Bill and Melinda Gates Foundation through Johns Hopkins University | $97,000 | March 2021-December 2022 | |
| HIV and STI Biobehavioral Survey among High-Risk Men in selected Towns in Zambia Maria Lahuerta, Lauren Parmley Leigh Tally, Brave Hanunka Jackson Okuku, Joyce Neal Gaston Djomand, Lazarous Chelu Chipili Mulemfwe, John Mwale, Ray Handema, Bwalya Innocent, Kapungu Kelvin, Kondowe Shepherd | To estimate the HIV care cascade, population size, prevalence of HIV, syphilis, hepatitis B (HBV) and hepatitis C (HCV), coinfections, sexual risk behaviours and access to preventive care for high risk men living with HIV. | CDC through ICAP | $433,000 | October 2020 – | |
| Zambia HIV Recent Infection Surveillance Lloyd Mulenga Aaron Shibemba Gershom Chongwe Innocent Bwalya | Implement a recent HIV infection surveillance system in Zambia, including integration of recent infection testing into routine HIV testing services; proportion and demographics of clients with a recent HIV infection. | CDC,GRZ | | Nov 2019 – | |
| Routine data entry and management for COVID19 surveillance, Dr Gershom Chongwe, Dr Justin Chileshe, David Mwakazanga, Bridget M. Shanene, Lucy N. Phiri | To maintain an updated database of COVID19 test subjects and results | MOH/TDRC | Recurring cost | 2019-ongoing | |
| Using Household-centred Health Education and Routine Follow-up visits to improve utilization of preventive and control measures of Malaria among household-leaders and school children in Nchelenge District, Kelvin Kapungu and Dr. Mike Chaponda | To determine the effectiveness of Household-centred Health Education and Routine Follow-up visits for improving utilization of preventive and control measures of Malaria among household-leaders and school children in Nchelenge District. | ICEMR (Special Project) | $15,000.00 | May 2019 | |
| Pregnant women’s experiences and beliefs about Sexually Transmitted Infections in pregnancy and poor birth outcomes: A qualitative study to be conducted in Papua New Guinea (PNG) and Zambia, Dr. Chaponda and Kelvin Kapungu | To understand the lived experiences and beliefs of pregnant women diagnosed with gonorrhoea, chlamydia, syphilis or trichomoniasis during pregnancy and had a preterm birth and or neonatal birth | SNIS | $20,300 | January | |
| Patient and Provider Attitudes to, and Interest in, Long Acting Formulations of Malaria Prophylaxis. Prof. Susan Swindells, Kelvin Kapungu, Dr. Gershom Chongwe | To assess interest in and barriers associated with prescribing or receiving long-acting therapy to prevent malaria among individuals in areas with a high burden of malarial infection. | WHO-(Unitaid), through University of Nebraska | $50,000.00 | January to December 2021 | |
| International Centres of Excellence for Malaria Research (ICEMR) Project PI-Dr Mike Chaponda, Co PI Mr Mbanga Muleba | Overall, the project aims to provide knowledge on malaria control from different transmission patterns in southern and central Africa. For TDRC, the study provides insight on why high transmission is sustained in Nchelenge district despite the various interventions employed by the ministry of health and its partners. | National Institutes of Health (NIH) through JHU, Macha Research Trust, Biomedical Research and Training Institute, Harare, Zimbabwe, University of Witwatersrand, Universite Protestante au Congo, Kinshasa, DRC. | $420,000 | 1st April 2017 to 31st March 2024 | |
| Safety and Efficacy of Intermittent Presumptive Treatment in pregnancy with Sulfadoxine-Pyrimethamine using Rapid Diagnostic Test Screening And Treatment at First Antenatal Care Visit, PI-Dr. Jean-Bertin Bukasa Kabuya, Co-Investigator Dr. Christine Manyando | To evaluate the impact of adding, at first ANC, mRDT screening and treatment with DHA-PQ to the current IPTp-SP (IPTp-SP+) on IPT-SP efficacy at clearing maternal peripheral parasitemia and at preventing maternal anemia, LBW and neonatal mortality. | European and Developing Countries Clinical Trial Partnership (EDCTP) through TDRC | € 149,999.33 | 26/04/2019 to 30/06/2021 | |
| Management of Malaria in African Countries: A multicenter, prospective, non-interventional study, PI: Dr S Hachizovu (Ipafu site), Co-Investigators: Dr Christine Manyando, Dr Jonathan Gwasupika | To describe the treatment prescribed (including adherence to WHO guidelines) to patients with a confirmed diagnosis of malaria, either uncomplicated or severe in real-life settings in Africa | NOVARTIS | $37, 375 | 1st Oct 2020, end date to be communicated | |
| Field study of the pharmacokinetics and pharmacodynamics of artemisinin-based combination therapy for gametocyte clearance in Zambian children with uncomplicated falciparum malaria (PHARCIDE), PI-Dr JB Kabuya | To model the pharmacokinetic and pharmacodynamic (PK/PD) profiles of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for gametocyte clearance | Johns Hopkins Bloomberg School of Public health with funding from the NIH | First grant 2017/2: $49,000, Subgrant/award 2019/10: $ 60,199, | | |
